Late characterisation of cardiac effects following anthracycline and trastuzumab treatment in breast cancer patients by Kimball, Ashlee et al.
Archived at the Flinders Academic Commons: 
http://dspace.flinders.edu.au/dspace/ 
‘This is the peer reviewed version of the following article: 
Kimball, A., Patil, S., Koczwara, B., Raman, K. S., Perry, R., 
Grover, S., & Selvanayagam, J. (2018). Late 
characterisation of cardiac effects following anthracycline 
and trastuzumab treatment in breast cancer patients. 
International Journal of Cardiology, 261, 159–161. https://
doi.org/10.1016/j.ijcard.2018.03.025 
which has been published in final form at 
https://doi.org/10.1016/j.ijcard.2018.03.025
© 2018 Elsevier B.V.. This manuscript version is made 
available under the CC-BY-NC-ND 4.0 license:
http://creativecommons.org/licenses/by-nc-nd/4.0/ 
Accepted Manuscript
Late characterisation of cardiac effects following anthracycline
and trastuzumab treatment in breast cancer patients
Ashlee Kimball, Sanjana Patil, Bogda Koczwara, Karthigesh Sree





Received date: 30 October 2017
Revised date: 5 February 2018
Accepted date: 6 March 2018
Please cite this article as: Ashlee Kimball, Sanjana Patil, Bogda Koczwara, Karthigesh
Sree Raman, Rebecca Perry, Suchi Grover, Joseph Selvanayagam , Late characterisation
of cardiac effects following anthracycline and trastuzumab treatment in breast cancer
patients. The address for the corresponding author was captured as affiliation for all
authors. Please check if appropriate. Ijca(2017), doi:10.1016/j.ijcard.2018.03.025
This is a PDF file of an unedited manuscript that has been accepted for publication. As
a service to our customers we are providing this early version of the manuscript. The
manuscript will undergo copyediting, typesetting, and review of the resulting proof before
it is published in its final form. Please note that during the production process errors may

















Late Characterisation of Cardiac Effects Following Anthracycline and Trastuzumab Treatment in 
Breast Cancer Patients 
Ashlee Kimball1, Sanjana Patil2, Bogda Koczwara3, Karthigesh Sree Raman4, Rebecca Perry5, Suchi 
Grover,6, Joseph Selvanayagam7  
Corresponding author: Joseph Selvanayagam joseph.selvanayagam@flinders.edu.au 
No conflict of interest to declare 
Keywords: chemotherapy, cardiotoxicity, breast cancer, cardiac magnetic resonance imaging, T1-mapping, left 





                                                          
1 College of Medicine, Flinders University of South Australia  
"This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation". 
2
 
College of Medicine, Flinders University of South Australia  
Cardiac Imaging Research Group, South Australian Health and Medical Research Institute 
"This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation". 
3
 
Department of Medical Oncology, Flinders Centre for Innovation in Cancer, Adelaide, Australia 
"This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation". 
4
 
College of Medicine, Flinders University of South Australia,  
Cardiac Imaging Research Group, South Australian Health and Medical Research Institute 
Department of Cardiovascular Medicine, Flinders Medical Centre, Southern Adelaide Local Health Network 
"This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation". 
5
 
College of Medicine, Flinders University of South Australia,  
Cardiac Imaging Research Group, South Australian Health and Medical Research Institute 
Department of Cardiovascular Medicine, Flinders Medical Centre, Southern Adelaide Local Health Network 
"This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation". 
6 College of Medicine, Flinders University of South Australia
 
Department of Cardiovascular Medicine, Flinders Medical Centre, Southern Adelaide Local Health Network 
Cardiac Imaging Research Group, South Australian Health and Medical Research Institute 
"This author takes responsibility for all aspects of the reliability and freedom from bias of the data presented and their discussed interpretation". 
7
 
College of Medicine, Flinders University of South Australia
 
Department of Cardiovascular Medicine, Flinders Medical Centre, Southern Adelaide Local Health Network 
Cardiac Imaging Research Group, South Australian Health and Medical Research Institute 



















Background: Anthracycline (A) and trastuzumab (T) chemotherapy have well recognized cardiac 
toxicity, potentially leading to significant morbidity and mortality.  Our previous work in 46 
prospectively enrolled breast cancer patients showed early left ventricular (LV) and right ventricular 
(RV) function decline at 1 and 3 months, but only persistent RV dysfunction at 12 months which 
correlated with myocardial oedema observed early (1 and 3 months) after administration of 
chemotherapy regimes.  
Method: To investigate late cardiac effects, the same cohort were re-imaged with advanced 
Cardiovascular Magnetic Resonance (CMR) imaging including T1 mapping 5 +/- 1 year post 
chemotherapy. 
Results: 26 out of 46 (50%) patients underwent follow up imaging. A statistical but non-clinically 
significant decrease was observed in LV ejection fraction (EF) from baseline to 5 years (72.2±6.6 to 
65.4±9.3, p<0.005). Subjects with initial drop of LVEF by >10% at 3 months (n=5) or at 12 months 
(n=3) did not demonstrate any difference in LV or RVEF at 5 years.  No correlation was observed 
between myocardial oedema and LV or RVEF at 5 years. At 5 years, T1 values were within normal 
limits overall (935± 48ms).  One patients had significantly elevated (>1000ms) T1 values with no 
correlation to LV or RVEF.  No subjects demonstrated replacement myocardial fibrosis at 5 years. 
Conclusion: Using advanced CMR, contemporary chemotherapy regimes demonstrate minimal long 
term cardiac toxicity.  There is minimal diffuse and no replacement fibrosis as demonstrated by LGE, 




















Post-chemotherapy cardiotoxic effects have been recognised  as the main contributor to both acute 
and late non-cancer related mortality in breast cancer patients treated with adjuvant chemotherapy 
[1]. Early detection of this occurrence is essential to introduce  alternative treatment strategies 
and/or commence cardioprotective therapy (such as renin-angiotensin aldosterone system 
inhibition) [1]. Cardiovascular magnetic resonance (CMR) is the gold standard for accurate and 
reproducible assessment of right ventricular (RV) and left ventricular (LV) volumes, function and 
mass [2]. Furthermore, modalities such as T1 mapping and late-gadolinium enhancement (LGE) 
enable myocardial tissue characterization including assessment of myocardial oedema, replacement 
fibrosis and diffuse fibrosis [3] [4]. Previously, we utilised these CMR parameters in chemotherapy 
naïve breast cancer participants receiving anthracycline and/or trastuzumab treatment to 
demonstrate early LV and RV functional decline at 1 and 4 months, but only persistent RV 
dysfunction at 12 months[5]. This decline was found to correlate to early myocardial oedema 
observed at 1 and 4 months. To investigate the late effects of these same treatments, the same 
patient cohort was reimaged with CMR 60±12 months post chemotherapy. Our primary aim was to 
assess, using multiparametic CMR,  the long term structural and functional effects of anthracycline 
+/- trastuzumab (Herceptin) exposure in these patients, and compare the late findings with early 
post chemotherapy LV/RV changes.  
Participants underwent cine, LGE and T1 mapping CMR imaging. T1 mapping was performed with 
the shMOLLI technique [6]. Normal T1 values were established in healthy volunteers as values 
between 950-980, with global T1 greater than 1000 being considered as abnormal, consistent with 
previous T1 mapping literature [7] [8]. LGE enhancement was assessed qualitatively and 
quantitatively as previously described [5]Echocardiography was performed for LV volumes and 
function, diastolic parameters (including mitral inflow for E:A ratio, tissue Doppler imaging for early 
diastolic mitral annular motion at both the septal and lateral annulus, E’ and left atrial volumes) and 

















Table 1: Baseline clinical and chemotherapy characteristics  
 
Baseline and clinical characteristics of the study population are described in Table 1. 26 of the 
original 46 (57%) participants returned for follow-up CMR and echocardiograms after 60 months. 
This reduced rate of follow-up was attributed to a number of factors; 5 of the original 46 (11%) 
participants were deceased, however none were due to cardiovascular complications, 5 (11%)  had 
moved interstate or overseas, 8 (17%) were unwilling to participate for varying reasons, and 1 
(approx. 2%)  was unable to complete the scan due to claustrophobia. In the initial study, one 
participant was found to demonstrate cardiotoxicity at 12 months and was therefore not included in 
this current  study.  
Global T1 values were within normal limits for all participants, (935+/-48ms), except one who 
demonstrated elevated T1 (>1000ms). There was no correlation between T1 values and RVEF or 
LVEF at 60 months. LGE findings did not demonstrate replacement myocardial fibrosis in any 
participants at 5 years. All echo parameters remained stable from baseline to 60 months (table 2). 
Variable (n=26)  
Age (years) 53.1±9.6 
Chemotherapy regime Anthracycline (%) Trastuzumab (%) Combined (%) 
62 30 8 
Systolic blood pressure 
(mmHg) 
115.3±16.1 
Diastolic blood pressure 
(mmHg) 
66.5±10.2 
Height (m) 1.63±0.1 

















Table 2: CMR characteristics from baseline to 60 months  
Time 
point 
LVEDV (mL) LVESV (mL) LVEF (%) GLS (echo, 
%) 
RVEDV (mL) RVESV (mL) RVEF (%) 
Baseline 115.9±23.2  33.9±12.6 72.2±6.6 -21.8±3.2 116.1±26.4 45.3±11.6 60.9±6.0 
1 month 116.9±21.3 36.7±13.0* 69.0±7.0* -21.3±2.7 121.6±28.7* 52.4±14.3* 56.9±5.9 
3 month 115.8±21 42.3±14.2* 65.0±6.7* -19.5±2.0* 117.8±23.4* 52.1±13.0* 56.5±6.4 
12 
months 
125.1±24.8 44.7±17.0* 65.1±6.9* -19.7±2.2 122.6±19.0* 57.5±12.8* 53.3±6.8 
60 
months 
109.1±27.1~ 38.51±17.4*~ 65.4±9.3* -21.2±2.8 103.5±20.8*~ 37.8±12.2*~ 63.8±7.9~ 
*statistically significant from baseline 
~60 month data different from 12 month data 
 
Despite our previous findings depicting significant functional changes in RV and LV at 12 months, our 
long term follow up data did not show continuation of this effect at 60 months. A statistically 
significant drop in left ventricular ejection fraction (LVEF) was observed from baseline to 12 months 
(72.2% to 65.1%, p=0.004, table 2); however this was unchanged from 12 months to 60 months, and 
still within normal range of LVEF. Hence, there was no clinically significant change in systolic function 
based on our data. Of importance, there was not any difference in LVEF or RVEF at 60 months in 
those participants that originally demonstrated a decrease of >10% in either of these parameters. 
There was not any correlation of myocardial oedema with either LVEF or RVEF at 60 months, as we 
previously observed at 12 months.  
To the best of our knowledge, our study is the first to assess long-term cardiotoxicity in post 
chemotherapy patients utilising T1 mapping in CMR. Our principal findings demonstrate three main 

















underlying myocardial damage due to chemotherapy. (2) Significant functional changes in both the 
LV and RV, as detected by CMR, indicate injury starting  3 months and persisting to 12 months, but 
these are reversed at 60 months. (3) This phenomenon is consistent with no minimal diffuse fibrosis, 
no replacement fibrosis and no myocardial oedema at 60 months.  
Anthracylines and trastuzumab are well known for their cardiotoxic effects, however previous 
studies looking at cardiotoxicity have tended to be retrospective and short-term. Although previous 
studies have conducted T1 mapping on post- chemotherapy patients up to three months, to our 
knowledge we are the first study evaluating this modality at 5 years, detecting no significant 
elevation of T1 values [9]. Cardiotoxicity tends to be demonstrated through damage to the 
myocardium, generally shown as fibrosis through tissue characterisation methods such as  T1 
mapping and LGE. High T1 values (>1000ms) are indicative of an increase in interstitial space as seen 
in diffuse myocardial fibrosis or oedema and it is reassuring that this prospective serially followed 
chemotherapy cohort did not demonstrate this. Similarly, the initial increase in oedema in a third of 
our patients at 1 month and in almost half our participants at either 1 or 4 months was resolved by 
60 months, demonstrating no long term injury.   
Anthracycline-induced cardiotoxicity tends to be detected using echocardiographic studies and is 
clinically followed up to evaluate LV function. However, due to significant interstudy and 
interobserver variability, it is possible that underlying early damage may be missed by this 
technique, and hence  echocardiography is not as effective in detecting early prognostic markers 
[10]. Biopsy remains the gold standard of myocardial damage assessment post chemotherapy, 
however it is an invasive process and the ability to predict clinical outcome is questionable  [10]. 
Hence, CMR remains the optimal tool for non-invasive detection of subclinical cardiotoxicity which 
may otherwise go unidentified. In particular, CMR modalities such as T1, T2 relaxation times and 
late-gadolinium enhancement provide further tissue characterisation giving new insight disease 

















Interestingly, we observed a marked, but non-clinically significant drop in LVEF at 3 months, which, 
based on previous studies, may be considered a sign of acute cardiotoxicity, however this was not 
sustained at 60 months, indicating chronic cardiotoxicity was not an issue for these patients. 
Previous studies have indicated that subacute and chronic forms of anthracycline-induced 
cardiotoxicity tend not to be reversible, but the prospectively collected CMR data from this study is 
not consistent with this. Despite the initial decrease in both LVEF at 3 months, and RVEF at 12 
months, there was an improvement in the 60 month data, tending back to baseline [11]. This may be 
indicative of RV function being restored, a feature which is not completely understood, or 
alternatively, related to serial imaging assessment being done by CMR (a more reproducible 
technique) than 2D echocardiography.  
Previously papers have indicated that changes in GLS tend to occur prior to LVEF dysfunction, 
however our study demonstrates synonymous changes, with both LVEF and GLS tending to decrease 
around 3 months [12]. However, this may be due to previous studies utilising echocardiography to 
determine LVEF, whereas we determined this value through CMR techniques, a more precise marker 
of global LV function.  
The European Society of Medical Oncology guidelines recommend left ventricular dysfunction 
assessment at three month intervals for a 12 month duration, after which annual echos should be 
undertaken [13, 14]. However, the guidelines do not specify how this dysfunction be assessed and a 
decrease in LVEF, as determined through 2D echocardiography, is the current marker to confirm 
post-chemotherapy cardiotoxicity. In our study, the LVEF remained within a clinically normal range 
throughout the 60 months, and was assessed with advanced CMR imaging, as opposed to 
echocardiography. Furthermore; as no new long-term cardiotoxicity occured in those patients 
without 12 month cardioxicity, we propose that long-term (60 months) follow-up advanced imaging 

















A limitation of this study is the small sample size in the original cohort (n=46)  which further 
decreased (n=26) by the 60 months follow up. Hence, a larger sample of patients needs to be 
investigated. The dose-dependency of the cardiotoxicity was also not identified, which may also be 
correlated with cardiotoxicity [15]. Hence, based on our results,  we can conclude that as no long 
term cardiotoxicity occurred in our cohort, thesepatients may only need echocardiographic or CMR 
follow up for the first 12 months post commencement of anthracycline and or trastuzumab 
chemotherapy. However, this cannot be generalised across all breast cancer therapy patients, as 
different chemotherapy regimes, and particularly different doses, may require more strict 
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 Advanced CMR demonstrated no long-term cardiotoxicity in post-chemotherapy breast 
cancer patients 
 T1 Mapping and Late Gadolinium Enhancement indicated no significant replacement or 
diffuse fibrosis in long-term post- chemotherapy patients 
 Limiting long-term serial imaging in post-chemotherapy patients is proposed, depending on 
the dose and drug type.   
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